| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f1e9f0d3d21b54d01ba8cbc32d13104 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2210-0606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M27-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M27-00 |
| filingDate |
2013-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22fd37511096a4828f34b06e8f73c56c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_242353ccf8ec97dd7396955ea6671986
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cdd2394da089b3008212fae5ed1474e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b38502b935fd759a0bba5f3304703cc |
| publicationDate |
2015-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9089392-B2 |
| titleOfInvention |
Drug delivery devices and methods |
| abstract |
This disclosure relates generally to methods and devices for use in treating eye conditions with implantable drug delivery devices. One method includes introducing an implant into the suprachoroidal space, wherein the interior volume of the implant is plugged with a drug-release material comprising at least one active agent that elutes through at least one opening in the implant, wherein the drug-release material degrades from the interior volume of the implant over a period time. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018071143-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344448-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400044-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10531983-B2 |
| priorityDate |
2009-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |